New drug combo shows promise for Hard-to-Treat prostate cancer
NCT ID NCT04751929
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that has stopped responding to hormone therapy. Nineteen adult men with metastatic castration-resistant prostate cancer took part. The goal is to see if the combination is safe and effective at controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.